|
Leiden, The Netherlands, November 5, 2002 - Dutch antibody and vaccine company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has appointed Mr. Arie C. Bos as its Director Corporate Communications as per December 1, 2002. Mr. Bos will be responsible for Crucell's internal and external communications.
Mr. Bos currently works for Hill and Knowlton, but has been working on an interim management basis at Crucell since October 1, 2002. Prior to this, Mr. Bos was Group Director of Hill and Knowlton Financial in Amsterdam, part of Hill and Knowlton B.V, a communications consultancy company. In this role he acted as financial communications advisor to a number of Hill and Knowlton's client companies.
Before joining Hill and Knowlton, Mr. Bos worked as Senior Consultant Financial Communications at Adviesbureau Klijnsma & Bodes, a communications consultancy company based in The Hague. Mr. Bos has also worked as a journalist for Het Financieele Dagblad. He holds a law degree from Leiden University.
About Crucell
Crucell N.V. discovers and develops biopharmaceuticals that use the human immune system to combat cancer, infectious diseases and other conditions. Crucell leverages its patented technologies, MAbstract(TM), AdVac(TM), and PER.C6(TM), for discovery, development and production of antibodies and vaccines. Crucell offers its technologies to the pharmaceutical and biotechnology industry and also uses them to create its own product pipeline. Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of various types of cancer. In addition, Crucell has over 20 licensees for its PER.C6(TM) technology. These include Novartis, GSK, Aventis and Schering AG. With headquarters in Leiden, The Netherlands, the company currently employs 200 people. Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL). For more information visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2002, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States.
Please click on the link to view the formatted article:
5.11.02 Arie Bos
|
